Viewing data from:

ALMOTRIPTAN MALATE

ANDA

ALMOTRIPTAN MALATE | A078027 | TEVA PHARMACEUTICALS USA

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Almotriptan Malate (2023)

Total Spending

$1.7M

Total Claims

4,839

Beneficiaries

1,289

Avg Cost/Unit

$24.22

Spending Trend

$2.0M(2019)→$1.8M(2020)→$1.7M(2021)→$1.8M(2022)→$1.7M(2023)

YoY Change:+0.8%

5yr CAGR:+0.1%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain4 active DMFs1 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

SMS PHARMACEUTICALS LTDALMOTRIPTAN MALATE

DMF 189622005

MATRIX PHARMACORP PRIVATE LTDALMOTRIPTAN MALATE USP

DMF 204242007

MSN LABORATORIES PRIVATE LTDALMOTRIPTAN MALATE USP [ROUTE CODE - AM]

DMF 253272011

ORCHID PHARMA LTDALMOTRIPTAN MALATE

DMF 261772012

APOTEX PHARMACHEM INDIA PVT LTDInactiveALMOTRIPTAN MALATE

DMF 252252011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jul 10, 2015	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — EQ 6.25MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jul 7, 2015

No patent or exclusivity listings for this strength.

#002 — EQ 12.5MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jul 7, 2015